Overview

TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Status:
Active, not recruiting

Trial end date:
2022-07-31

Target enrollment:

Participant gender:

Summary

A phase 3, randomized, open-label, parallel-controlled, multi-center study comparing TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in subjects with relapsed or refractory multiple myeloma who received at least 1 prior line of treatment

Phase:

Phase 3

Details

Lead Sponsor:

I-Mab Biopharma Co. Ltd.
I-Mab Biopharma HongKong Limited

Treatments:

BB 1101
Dexamethasone
Dexamethasone acetate
Lenalidomide